Global market valuation was derived through revenue mapping, procedure volume analysis, and educational intervention adoption metrics. The methodology included:
Identification of 50+ key manufacturers and service providers across North America, Europe, Asia-Pacific, and Latin America, spanning pharmaceutical companies (Bristol-Myers Squibb, etc.), educational publishers (Pearson, Houghton Mifflin Harcourt, Scholastic), edtech providers (Lexia Learning, Learning Ally, Dyslexia Gold, Nessy, MindPlay, Read Naturally), and assistive technology developers
Product mapping across medication categories (antihistamines, CNS stimulants, anti-myoclonic agents, ADHD drugs), educational intervention tools (E-readers, tablets, specialized apps, smartpens, multisensory learning platforms), diagnostic solutions (paper-based assessments, AI-driven digital screening tools, neuroimaging devices), and end-user settings (specialty centers, home care, hospitals & clinics, school-based programs)
Analysis of reported and modeled annual revenues specific to dyslexia treatment portfolios, including pharmaceutical sales for off-label and indicated uses, educational software licensing, assistive technology hardware and subscription revenues, and professional therapy services
Coverage of manufacturers and service providers representing 72-78% of global market share in 2024
Extrapolation using bottom-up (treatment adoption rates × average spend per patient by country/region, segmented by age group and severity level) and top-down (manufacturer revenue validation, edtech market sizing, pharmaceutical therapeutic area allocation) approaches to derive segment-specific valuations for educational interventions, behavioral therapy, medication, and assistive technology verticals